Damien Levard

Damien Levard

Auto-generated profile, based on publicly available information

Damien Levard

Normandie University, Caen Normandie University, UNICAEN, INSERM U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), Cyceron, Institut Blood and Brain @ Caen-Normandie (BB@C), Caen, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Therapeutic Advances in Neurological Disorders
Verified
Journal Article
Open access
PDF file
ADAntoine Drieu
Antoine Drieu
DLDamien Levard
Damien Levard
DVDenis Vivien
Denis Vivien
MRMarina Rubio
Marina Rubio
So far, intravenous tissue-type plasminogen activator (tPA) and mechanical removal of arterial blood clot (thrombectomy) are the only available treatments for acute ischemic stroke. However, the short therapeutic window and the lack of specialized stroke unit care make the overall availability of both treatments limited. Additional agents to combine with tPA administration or thrombectomy to enhance efficacy and improve outcomes associated with stroke are needed. Stroke-induced inflammatory processes are a response to the tissue damage due to the absence of blood supply but have been proposed also as key contributors to all the stages of the ischemic stroke pathophysiology. Despite promising results in experimental studies, inflammation-modulating treatments have not yet been translated successfully into the clinical setting. This review will (a) describe the timing of the stroke immune pathophysiology; (b) detail the immune responses to stroke sift-through cell type; and (c) discuss the pitfalls on the translation from experimental studies to clinical trials testing the therapeutic pertinence of immune modulators.

3 July 2024 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
DLDamien Levard
Damien Levard
CSCélia Seillier
Célia Seillier
MBMathys Bellemain-Sagnard
Mathys Bellemain-Sagnard
AFAntoine Philippe Fournier
Antoine Philippe Fournier
ELEloïse Lemarchand
Eloïse Lemarchand
MRMarina Rubio
Marina Rubio

14 September 2019 in Translational Stroke Research
Verified
Journal Article
Closed access
PDF file
ADAntoine Drieu
Antoine Drieu
IBIzaskun Buendia
Izaskun Buendia
DLDamien Levard
Damien Levard
PHPauline Hélie
Pauline Hélie
CBCamille Brodin
Camille Brodin
MRMarina Rubio
Marina Rubio

27 February 2020 in JCI Insight
Verified
Journal Article
Closed access
PDF file
ADAntoine Drieu
Antoine Drieu
ALAnastasia Lanquetin
Anastasia Lanquetin
DLDamien Levard
Damien Levard
MGMartina Glavan
Martina Glavan
Francisco CamposFrancisco Campos
Francisco Campos
MRMarina Rubio
Marina Rubio
Alcohol abuse is a major public health problem worldwide, causing a wide range of preventable morbidity and mortality. In this translational study, we show that heavy drinking (HD) (≥6 standard drinks/day) is independently associated with a worse outcome for ischemic stroke patients. To study the underlying mechanisms of this deleterious effect of HD, we performed an extensive analysis of the brain inflammatory responses of mice chronically exposed or not to 10% alcohol before and after ischemic stroke. Inflammatory responses were analyzed at the parenchymal, perivascular, and vascular levels by using transcriptomic, immunohistochemical, in vivo 2-photon microscopy and molecular MRI analyses. Alcohol-exposed mice show, in the absence of any other insult, a neurovascular inflammatory priming (i.e., an abnormal inflammatory status including an increase in brain perivascular macrophages [PVM]) associated with exacerbated inflammatory responses after a secondary insult (ischemic stroke or LPS challenge). Similar to our clinical data, alcohol-exposed mice showed larger ischemic lesions. We show here that PVM are key players on this aggravating effect of alcohol, since their specific depletion blocks the alcohol-induced aggravation of ischemic lesions. This study opens potentially new therapeutic avenues aiming at blocking alcohol-induced exacerbation of the neurovascular inflammatory responses triggered after ischemic stroke.

9 August 2022 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Closed access
ADAntoine Drieu
Antoine Drieu
ALAnastasia Lanquetin
Anastasia Lanquetin
PPPaul Prunotto
Paul Prunotto
ZGZuhal Gulhan
Zuhal Gulhan
SPSwannie Pédron
Swannie Pédron
CACarine Ali
Carine Ali
Despite an apparently silent imaging, some patients with mild traumatic brain injury (TBI) experience cognitive dysfunctions, which may persist chronically. Brain changes responsible for these dysfunctions are unclear and commonly overlooked. It is thus crucial to increase our understanding of the mechanisms linking the initial event to the functional deficits, and to provide objective evidence of brain tissue alterations underpinning these deficits. We first set up a murine model of closed-head controlled cortical impact, which provoked persistent cognitive and sensorimotor deficits, despite no evidence of brain contusion or bleeding on MRI, thus recapitulating features of mild TBI. Molecular MRI for P-selectin, a key adhesion molecule, detected no sign of cerebrovascular inflammation after mild TBI, as confirmed by immunostainings. By contrast, in vivo PET imaging with the TSPO ligand [18F]DPA-714 demonstrated persisting signs of neuroinflammation in the ipsilateral cortex and hippocampus after mild TBI. Interestingly, immunohistochemical analyses confirmed these spatio-temporal profiles, showing a robust parenchymal astrogliosis and microgliosis, at least up to 3 weeks post-injury in both the cortex and hippocampus. In conclusion, we show that even one single mild TBI induces long-term behavioural deficits, associated with a persistent neuro-inflammatory status that can be detected by PET imaging.

12 March 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
FLFlorent Lebrun
Florent Lebrun
DLDamien Levard
Damien Levard
ELEloïse Lemarchand
Eloïse Lemarchand
MYMervé Yetim
Mervé Yetim
JFJonathane Furon
Jonathane Furon
DVDenis Vivien
Denis Vivien
The pharmacological intervention for ischemic stroke hinges on intravenous administration of the recombinant tissue-type plasminogen activator (rtPA, Alteplase/Actilyse) either as a standalone treatment or in conjunction with thrombectomy. However, despite its clinical significance, broader use of rtPA is constrained because of the risk of hemorrhagic transformations (HTs). Furthermore, the presence of diabetes or chronic hyperglycemia is associated with an elevated risk of HT subsequent to thrombolysis. This detrimental impact of tPA on the neurovascular unit in patients with hyperglycemia has been ascribed to its capacity to induce endothelial N-methyl-D-aspartate receptor (NMDAR) signaling, contributing to compromised blood-brain barrier integrity and neuroinflammatory processes. In a mouse model of thromboembolic stroke with chronic hyperglycemia, we assessed the effectiveness of rtPA and N-acetylcysteine (NAC) as thrombolytic agents. We also tested the effect of blocking tPA/NMDAR signaling using a monoclonal antibody, Glunomab. Magnetic resonance imaging, speckle contrast imaging, flow cytometry, and behavioral tasks were used to evaluate stroke outcomes. In hyperglycemic animals, treatment with rtPA resulted in lower recanalization rates and increased HTs. Conversely, NAC treatment reduced lesion sizes while mitigating HTs. After a single administration, either in standalone or combined with rtPA-induced thrombolysis, Glunomab reduced brain lesion volumes, HTs, and neuroinflammation after stroke, translating into improved neurological outcomes. Additionally, we demonstrated the therapeutic efficacy of Glunomab in combination with NAC or as a standalone strategy in chronic hyperglycemic animals. Counteracting tPA-dependent endothelial NMDAR signaling limits ischemic damages induced by both endogenous and exogenous tPA, including HTs and inflammatory processes after ischemic stroke in hyperglycemic animals.